ARFIP1 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 2.45969911105703E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.25370000048086E-07 |
Normal-vs-Stage2 |
2.185200E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
6.141300E-03 |
Stage1-vs-Stage2 |
3.412600E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
1.911970E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
6.502800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
5.35980149152238E-11 |
Normal-vs-AfricanAmerican |
3.249000E-01 |
Normal-vs-Asian |
5.951900E-02 |
Caucasian-vs-AfricanAmerican |
4.966600E-01 |
Caucasian-vs-Asian |
2.483600E-01 |
AfricanAmerican-vs-Asian |
8.839400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.03839999998634E-06 |
Normal-vs-Female |
1.35409999990621E-07 |
Male-vs-Female |
3.419200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.435410E-03 |
Normal-vs-Extreme_Weight |
4.39760000000566E-05 |
Normal-vs-Obese |
3.597200E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
7.658800E-01 |
Normal_Weight-vs-Obese |
3.297600E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
5.173800E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.310180E-01 |
Normal-vs-Age(41-60Yrs) |
3.839100E-04 |
Normal-vs-Age(61-80Yrs) |
2.76939999821479E-08 |
Normal-vs-Age(81-100Yrs) |
3.760800E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.884800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.134800E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.922800E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.392210E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.311400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.260600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
5.242600E-01 |
Normal-vs-Grade 3 |
3.916000E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
5.170800E-01 |
Grade 2-vs-Grade 4 |
5.242600E-01 |
Grade 3-vs-Grade 4 |
3.916000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.88219995145289E-09 |
Normal-vs-N1 |
5.520700E-03 |
N0-vs-N1 |
1.796130E-02 |
|
|